SuanFarma-Header SuanFarma-Header

X

Find Approved Drugs for Genetic Disease in Clinical Development in CANADA

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): Plasminogen

            Therapeutic Area: Genetic Disease Product Name: Ryplazim

            Highest Development Status: Approved Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kedrion

            Deal Size: $5.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement June 23, 2021

            Details:

            This acquisition would include the Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) business operated through its subsidiaries, Prometic Bioproduction Inc., the Company’s plasma-derived therapeutics manufacturing facility (“PBP”), and Prometic Biotherapeutics Inc.